03 Dec Amphivena Presents at ASH First-in -Human Phase 1 Clinical Data on AMV564
Data Demonstrate AMV564’s Safety, Anti-Leukemic Activity, and Unique PK Profile SOUTH SAN FRANCISCO -- December 3, 2018 -- Amphivena Therapeutics, Inc., a privately held biotechnology company developing AMV564, a CD33/CD3 T cell engager for the treatment of Acute Myeloid...